Chronic Lymphocytic Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk Chronic Lymphatic Leukemia
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Bad Saarow, Germany
  • +29 more
2022-01-04
Jan 4, 2022
L
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Scottsdale, Arizona
  • +55 more
2022-01-12
Jan 12, 2022
A
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
Recruiting
  • Chronic Lymphocytic Leukemia
    • Calgary, Alberta, Canada
    • +12 more
    2022-01-12
    Jan 12, 2022
    T
    Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
    Recruiting
    • Chronic Lymphocytic Leukemia
    • Boston, Massachusetts
    • +2 more
    2022-01-12
    Jan 12, 2022
    T
    Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
    Recruiting
    • Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • East Melbourne, Victoria, Australia
    • +7 more
    2022-01-12
    Jan 12, 2022
    T
    Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Birmingham, Alabama
    • +49 more
    2022-01-12
    Jan 12, 2022
    N
    Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Birmingham, Alabama
    • +865 more
    2022-01-12
    Jan 12, 2022
    H
    Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
    Recruiting
    • Chronic Lymphocytic Leukemia
    • Follicular Lymphoma
    • obinutuzumab
    • Busan, Korea, Republic of
    • +15 more
    2022-01-12
    Jan 12, 2022
    T
    Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
    Enrolling by invitation
    • Chronic Lymphocytic Leukemia
    • Non Hodgkin Lymphoma
    • Huntsville, Alabama
    • +16 more
    2022-01-12
    Jan 12, 2022
    T
    Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
    Recruiting
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Chicago, Illinois
    • +2 more
    2022-01-12
    Jan 12, 2022
    P
    Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
    Recruiting
    • Chronic Lymphocytic Leukemia
    • +4 more
    • Acalabrutinib 2x100 MG Oral Capsule + alloSCT
    • Warszawa, Mazowieckie, Poland
    • +5 more
    2021-12-23
    Dec 23, 2021
    T
    Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • Obinutuzumab
    • +3 more
    • Huntsville, Alabama
    • +153 more
    2022-01-12
    Jan 12, 2022
    T
    Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy - 2021
    Completed
    • Chronic Lymphocytic Leukemia
    • Huntsville, Alabama
    • +14 more
    2022-01-12
    Jan 12, 2022
    T
    An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
    Enrolling by invitation
    • Chronic Lymphocytic Leukemia
    • Huntsville, Alabama
    • +86 more
    2022-01-12
    Jan 12, 2022
    N
    Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study
    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Obinutuzumab
    • +3 more
    • Birmingham, Alabama
    • +460 more
    2022-01-11
    Jan 11, 2022
    M
    Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
    Recruiting
    • Chronic Lymphocytic Leukemia
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-01-10
    Jan 10, 2022
    U
    Pneumococcal Pneumonia Vaccine Series (PCV13 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Pneumococcal 13-valent Conjugate Vaccine
    • +2 more
    • Salt Lake City, Utah
      Huntsman Cancer Institute/University of Utah
    2021-12-21
    Dec 21, 2021
    A
    ALICIA (Acalabrutinib in CLL Therapy)
    Recruiting
    • Chronic Lymphocytic Leukemia
      • Irkutsk, Russian Federation
      • +12 more
      2021-12-20
      Dec 20, 2021
      T
      Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation - 2021
      Completed
      • Chronic Lymphocytic Leukemia
      • Richter Syndrome
      • New York, New York
      • +3 more
      2021-12-21
      Dec 21, 2021
      A
      A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy - 2021
      Completed
      • Chronic Lymphocytic Leukemia
      • La Jolla, California
      • +14 more
      2021-12-29
      Dec 29, 2021
      H
      A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
      Recruiting
      • Chronic Lymphocytic Leukemia
      • Woolloongabba, Queensland, Australia
      • +2 more
      2022-01-06
      Jan 6, 2022
      N
      Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
      Recruiting
      • Chronic Lymphocytic Leukemia
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-01-06
      Jan 6, 2022
      N
      Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
      Recruiting
      • Waldenstrom Macroglobulinemia
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2022-01-05
        Jan 5, 2022
        G
        Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation - 2019
        Terminated
        • Chronic Lymphocytic Leukemia
        • Richter's Transformation
        • Obinutuzumab
        • Bonn, Germany
        • +6 more
        2021-12-16
        Dec 16, 2021
        G
        Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression
        Active, not recruiting
        • Chronic Lymphocytic Leukemia
        • Cologne, Germany
          German CLL Study Group
        2021-12-16
        Dec 16, 2021